메뉴 건너뛰기




Volumn 26, Issue 6, 2018, Pages 312-320

Sodium–Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus A Review of Large-Scale Cardiovascular Outcome Studies and Possible Mechanisms of Benefit

Author keywords

Cardiovascular outcome; Diabetes; SGLT2 inhibitors

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BROMOCRIPTINE; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV; EMPAGLIFLOZIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; METOPROLOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; REACTIVE OXYGEN METABOLITE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN;

EID: 85054414399     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0000000000000201     Document Type: Review
Times cited : (5)

References (89)
  • 1
    • 85039999004 scopus 로고    scopus 로고
    • Update of cardiovascular effects of older and newer anti-diabetic medications
    • [published online ahead of print May 29, 2017]
    • Eleftheriadou I, Grigoropoulou P, Liberopoulos E, et al. Update of cardiovascular effects of older and newer anti-diabetic medications [published online ahead of print May 29, 2017]. Curr Med Chem. doi: 10.2174/0929867324666170530075533.
    • Curr Med Chem
    • Eleftheriadou, I1    Grigoropoulou, P2    Liberopoulos, E3
  • 2
    • 84991813209 scopus 로고    scopus 로고
    • Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
    • Avogaro A, Fadini GP, Sesti G, et al. Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovasc Diabetol. 2016;15:111.
    • (2016) Cardiovasc Diabetol , vol.15 , pp. 111
    • Avogaro, A1    Fadini, GP2    Sesti, G3
  • 3
    • 84978839381 scopus 로고    scopus 로고
    • Liraglutide and cardiovascular outcomes in type 2 diabetes
    • Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
    • (2016) N Engl J Med , vol.375 , pp. 311-322
    • Marso, SP1    Daniels, GH2    Brown-Frandsen, K3
  • 4
    • 84883745765 scopus 로고    scopus 로고
    • Alogliptin after acute coronary syndrome in patients with type 2 diabetes
    • White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
    • (2013) N Engl J Med , vol.369 , pp. 1327-1335
    • White, WB1    Cannon, CP2    Heller, SR3
  • 5
    • 84937053742 scopus 로고    scopus 로고
    • Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
    • Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
    • (2015) N Engl J Med , vol.373 , pp. 232-242
    • Green, JB1    Bethel, MA2    Armstrong, PW3
  • 6
    • 84883765959 scopus 로고    scopus 로고
    • Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
    • Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
    • (2013) N Engl J Med , vol.369 , pp. 1317-1326
    • Scirica, BM1    Bhatt, DL2    Braunwald, E3
  • 7
    • 84980320178 scopus 로고    scopus 로고
    • Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications
    • Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752–772.
    • (2016) Circulation , vol.134 , pp. 752-772
    • Heerspink, HJ1    Perkins, BA2    Fitchett, DH3
  • 8
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
    • (2015) N Engl J Med , vol.373 , pp. 2117-2128
    • Zinman, B1    Wanner, C2    Lachin, JM3
  • 9
    • 85019120109 scopus 로고    scopus 로고
    • All-cause mortality in patients with diabetes under treatment with dapagliflozin: a population-based, open-cohort study in the Health Improvement Network Database
    • Toulis KA, Willis BH, Marshall T, et al. All-cause mortality in patients with diabetes under treatment with dapagliflozin: a population-based, open-cohort study in the Health Improvement Network Database. J Clin Endocrinol Metab. 2017;102:1719–1725.
    • (2017) J Clin Endocrinol Metab , vol.102 , pp. 1719-1725
    • Toulis, KA1    Willis, BH2    Marshall, T3
  • 10
    • 85015246236 scopus 로고    scopus 로고
    • Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes
    • Nyström T, Bodegard J, Nathanson D, et al. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19:831–841.
    • (2017) Diabetes Obes Metab , vol.19 , pp. 831-841
    • Nyström, T1    Bodegard, J2    Nathanson, D3
  • 11
    • 85034766786 scopus 로고    scopus 로고
    • Canagliflozin and cardiovascular and renal events in type 2 diabetes
    • Neal B, Perkovic V, Mahaffey KW, et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
    • (2017) N Engl J Med , vol.377 , pp. 644-657
    • Neal, B1    Perkovic, V2    Mahaffey, KW3
  • 12
    • 85048449544 scopus 로고    scopus 로고
    • Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
    • Mahaffey KW, Neal B, Perkovic V, et al.; CANVAS Program Collaborative Group. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137:323–334.
    • (2018) Circulation , vol.137 , pp. 323-334
    • Mahaffey, KW1    Neal, B2    Perkovic, V3
  • 13
    • 85047212827 scopus 로고    scopus 로고
    • Canagliflozin: Cui Bono?
    • Cavender MA, Kosiborod M. Canagliflozin: Cui Bono? Circulation. 2018;137:335–337.
    • (2018) Circulation , vol.137 , pp. 335-337
    • Cavender, MA1    Kosiborod, M.2
  • 14
    • 84902756416 scopus 로고    scopus 로고
    • Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
    • Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol. 2014;13:102.
    • (2014) Cardiovasc Diabetol , vol.13 , pp. 102
    • Zinman, B1    Inzucchi, SE2    Lachin, JM3
  • 15
    • 85013890365 scopus 로고    scopus 로고
    • Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial
    • Neal B, Perkovic V, Matthews DR, et al.; CANVAS-R Trial Collaborative Group. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. Diabetes Obes Metab. 2017;19:387–393.
    • (2017) Diabetes Obes Metab , vol.19 , pp. 387-393
    • Neal, B1    Perkovic, V2    Matthews, DR3
  • 16
    • 85019731757 scopus 로고    scopus 로고
    • CVD-REAL Investigators and Study Group*. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
    • Kosiborod M, Cavender MA, Fu AZ, et al.; CVD-REAL Investigators and Study Group*. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017;136:249–259.
    • (2017) Circulation , vol.136 , pp. 249-259
    • Kosiborod, M1    Cavender, MA2    Fu, AZ3
  • 17
    • 85028958040 scopus 로고    scopus 로고
    • Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study
    • Persson F, Nyström T, Jørgensen ME, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab. 2018;20:344–351.
    • (2018) Diabetes Obes Metab , vol.20 , pp. 344-351
    • Persson, F1    Nyström, T2    Jørgensen, ME3
  • 18
    • 84964773926 scopus 로고    scopus 로고
    • SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study
    • Abdul-Ghani M, Del Prato S, Chilton R, et al. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 2016;39:717–725.
    • (2016) Diabetes Care , vol.39 , pp. 717-725
    • Abdul-Ghani, M1    Del Prato, S2    Chilton, R3
  • 19
    • 84975698839 scopus 로고    scopus 로고
    • Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
    • Fitchett D, Zinman B, Wanner C, et al.; EMPA-REG OUTCOME® trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37:1526–1534.
    • (2016) Eur Heart J , vol.37 , pp. 1526-1534
    • Fitchett, D1    Zinman, B2    Wanner, C3
  • 20
    • 84979895487 scopus 로고    scopus 로고
    • Empagliflozin and progression of kidney disease in type 2 diabetes
    • Wanner C, Inzucchi SE, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
    • (2016) N Engl J Med , vol.375 , pp. 323-334
    • Wanner, C1    Inzucchi, SE2    Lachin, JM3
  • 21
    • 85021254729 scopus 로고    scopus 로고
    • Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
    • Cherney DZI, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:610–621.
    • (2017) Lancet Diabetes Endocrinol , vol.5 , pp. 610-621
    • Cherney, DZI1    Zinman, B2    Inzucchi, SE3
  • 25
    • 84964507777 scopus 로고    scopus 로고
    • SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
    • Sattar N, McLaren J, Kristensen SL, et al. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59:1333–1339.
    • (2016) Diabetologia , vol.59 , pp. 1333-1339
    • Sattar, N1    McLaren, J2    Kristensen, SL3
  • 26
    • 84958548824 scopus 로고    scopus 로고
    • Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
    • Sonesson C, Johansson PA, Johnsson E, et al. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol. 2016;15:37.
    • (2016) Cardiovasc Diabetol , vol.15 , pp. 37
    • Sonesson, C1    Johansson, PA2    Johnsson, E3
  • 27
    • 84962613532 scopus 로고    scopus 로고
    • Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
    • Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4:411–419.
    • (2016) Lancet Diabetes Endocrinol , vol.4 , pp. 411-419
    • Wu, JH1    Foote, C2    Blomster, J3
  • 28
    • 84982863293 scopus 로고    scopus 로고
    • Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
    • Monami M, Dicembrini I, Mannucci E. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetol. 2017;54:19–36.
    • (2017) Acta Diabetol , vol.54 , pp. 19-36
    • Monami, M1    Dicembrini, I2    Mannucci, E.3
  • 29
    • 84995814726 scopus 로고    scopus 로고
    • Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: a meta-analysis of placebo-controlled randomized trials
    • Saad M, Mahmoud AN, Elgendy IY, et al. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: a meta-analysis of placebo-controlled randomized trials. Int J Cardiol. 2017;228:352–358.
    • (2017) Int J Cardiol , vol.228 , pp. 352-358
    • Saad, M1    Mahmoud, AN2    Elgendy, IY3
  • 30
    • 19944432528 scopus 로고    scopus 로고
    • Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF
    • Deedwania PC, Giles TD, Klibaner M, et al.; MERIT-HF Study Group. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J. 2005;149:159–167.
    • (2005) Am Heart J , vol.149 , pp. 159-167
    • Deedwania, PC1    Giles, TD2    Klibaner, M3
  • 31
    • 0034814619 scopus 로고    scopus 로고
    • Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study
    • Goldstein S, Fagerberg B, Hjalmarson A, et al.; MERIT-HF Study Group. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol. 2001;38:932–938.
    • (2001) J Am Coll Cardiol , vol.38 , pp. 932-938
    • Goldstein, S1    Fagerberg, B2    Hjalmarson, A3
  • 32
    • 84875787136 scopus 로고    scopus 로고
    • Primary prevention of cardiovascular disease with a Mediterranean diet
    • Estruch R, Ros E, Salas-Salvadó J, et al.; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279–1290.
    • (2013) N Engl J Med , vol.368 , pp. 1279-1290
    • Estruch, R1    Ros, E2    Salas-Salvadó, J3
  • 33
    • 0032487931 scopus 로고    scopus 로고
    • Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
    • The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349–1357.
    • (1998) N Engl J Med , vol.339 , pp. 1349-1357
  • 34
    • 34548420712 scopus 로고    scopus 로고
    • Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
    • Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–840.
    • (2007) Lancet , vol.370 , pp. 829-840
    • Patel, A1    MacMahon, S2    Chalmers, J3
  • 35
    • 85026729294 scopus 로고    scopus 로고
    • Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
    • Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017;60:1620–1629.
    • (2017) Diabetologia , vol.60 , pp. 1620-1629
    • Griffin, SJ1    Leaver, JK2    Irving, GJ.3
  • 36
    • 84871373150 scopus 로고    scopus 로고
    • Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents
    • Vinik AI, Cincotta AH, Scranton RE, et al. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. Endocr Pract. 2012;18:931–943.
    • (2012) Endocr Pract , vol.18 , pp. 931-943
    • Vinik, AI1    Cincotta, AH2    Scranton, RE3
  • 37
    • 80054045839 scopus 로고    scopus 로고
    • Bromocriptine for diabetes mellitus type II
    • Valiquette G. Bromocriptine for diabetes mellitus type II. Cardiol Rev. 2011;19:272–275.
    • (2011) Cardiol Rev , vol.19 , pp. 272-275
    • Valiquette, G.1
  • 38
    • 77958179761 scopus 로고    scopus 로고
    • Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes
    • Gaziano JM, Cincotta AH, O’Connor CM, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010;33:1503–1508.
    • (2010) Diabetes Care , vol.33 , pp. 1503-1508
    • Gaziano, JM1    Cincotta, AH2    O’Connor, CM3
  • 39
    • 84929329277 scopus 로고    scopus 로고
    • Timed Bromocriptine-QR therapy reduces progression of cardiovascular disease and dysglycemia in subjects with well-controlled type 2 diabetes mellitus
    • Chamarthi B, Gaziano JM, Blonde L, et al. Timed Bromocriptine-QR therapy reduces progression of cardiovascular disease and dysglycemia in subjects with well-controlled type 2 diabetes mellitus. J Diabetes Res. 2015;2015:157698.
    • (2015) J Diabetes Res , vol.2015 , pp. 157698
    • Chamarthi, B1    Gaziano, JM2    Blonde, L3
  • 40
    • 84957441669 scopus 로고    scopus 로고
    • Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension
    • Tikkanen I, Chilton R, Johansen OE. Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension. Curr Opin Nephrol Hypertens. 2016;25:81–86.
    • (2016) Curr Opin Nephrol Hypertens , vol.25 , pp. 81-86
    • Tikkanen, I1    Chilton, R2    Johansen, OE.3
  • 41
    • 77953444272 scopus 로고    scopus 로고
    • Can nocturnal hypertension predict cardiovascular risk?
    • Friedman O, Logan AG. Can nocturnal hypertension predict cardiovascular risk? Integr Blood Press Control. 2009;2:25–37.
    • (2009) Integr Blood Press Control , vol.2 , pp. 25-37
    • Friedman, O1    Logan, AG.2
  • 42
    • 84928196614 scopus 로고    scopus 로고
    • Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension
    • Tikkanen I, Narko K, Zeller C, et al.; EMPA-REG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420–428.
    • (2015) Diabetes Care , vol.38 , pp. 420-428
    • Tikkanen, I1    Narko, K2    Zeller, C3
  • 43
    • 84880850027 scopus 로고    scopus 로고
    • Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
    • Lambers Heerspink HJ, de Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853–862.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 853-862
    • Lambers Heerspink, HJ1    de Zeeuw, D2    Wie, L3
  • 44
    • 84923474324 scopus 로고    scopus 로고
    • BP reduction with the sodium glucose co-transporter 2 inhibitor empagliflozin in type 2 diabetes is similar in treatment naïve as in those on one or 2 antihypertensive agents—further insights from a Dedicated 24h ABPM Study
    • Mancia G, Cannon CP, Tikkanen I, et al. BP reduction with the sodium glucose co-transporter 2 inhibitor empagliflozin in type 2 diabetes is similar in treatment naïve as in those on one or 2 antihypertensive agents—further insights from a Dedicated 24h ABPM Study. Circulation. 2014;129:A2343.
    • (2014) Circulation , vol.129 , pp. A2343
    • Mancia, G1    Cannon, CP2    Tikkanen, I3
  • 45
    • 84893214045 scopus 로고    scopus 로고
    • Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus
    • Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587–597.
    • (2014) Circulation , vol.129 , pp. 587-597
    • Cherney, DZ1    Perkins, BA2    Soleymanlou, N3
  • 46
    • 85021069048 scopus 로고    scopus 로고
    • Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes
    • Hammoudi N, Jeong D, Singh R, et al. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes. Cardiovasc Drugs Ther. 2017;31:233–246.
    • (2017) Cardiovasc Drugs Ther , vol.31 , pp. 233-246
    • Hammoudi, N1    Jeong, D2    Singh, R3
  • 47
    • 85020395878 scopus 로고    scopus 로고
    • EMPA-REG OUTCOME: the cardiologist’s point of view
    • Pham SV, Chilton RJ. EMPA-REG OUTCOME: the cardiologist’s point of view. Am J Cardiol. 2017;120(1S):S53–S58.
    • (2017) Am J Cardiol , vol.120 , Issue.1S , pp. S53-S58
    • Pham, SV1    Chilton, RJ.2
  • 48
    • 84945455839 scopus 로고    scopus 로고
    • Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
    • Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17:1180–1193.
    • (2015) Diabetes Obes Metab , vol.17 , pp. 1180-1193
    • Chilton, R1    Tikkanen, I2    Cannon, CP3
  • 49
    • 84995685476 scopus 로고    scopus 로고
    • A new era in the management of type 2 diabetes: is cardioprotection at long last a reality?
    • Rossello X, Yellon DM. A new era in the management of type 2 diabetes: is cardioprotection at long last a reality? Int J Cardiol. 2017;228:198–200.
    • (2017) Int J Cardiol , vol.228 , pp. 198-200
    • Rossello, X1    Yellon, DM.2
  • 50
    • 42349104656 scopus 로고    scopus 로고
    • Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis
    • Nakagami H, Kaneda Y, Ogihara T, et al. Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis. Curr Diabetes Rev. 2005;1:59–63.
    • (2005) Curr Diabetes Rev , vol.1 , pp. 59-63
    • Nakagami, H1    Kaneda, Y2    Ogihara, T3
  • 51
    • 85021710250 scopus 로고    scopus 로고
    • Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
    • Shigiyama F, Kumashiro N, Miyagi M, et al. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol. 2017;16:84.
    • (2017) Cardiovasc Diabetol , vol.16 , pp. 84
    • Shigiyama, F1    Kumashiro, N2    Miyagi, M3
  • 52
    • 84975501232 scopus 로고    scopus 로고
    • Changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics during treatment with dapagliflozin among obese type 2 diabetes mellitus patients
    • Okamoto A, Yokokawa H, Sanada H, et al. Changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics during treatment with dapagliflozin among obese type 2 diabetes mellitus patients. Drugs R D. 2016;16:255–261.
    • (2016) Drugs R D , vol.16 , pp. 255-261
    • Okamoto, A1    Yokokawa, H2    Sanada, H3
  • 53
    • 84885476895 scopus 로고    scopus 로고
    • Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
    • Tahara A, Kurosaki E, Yokono M, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715:246–255.
    • (2013) Eur J Pharmacol , vol.715 , pp. 246-255
    • Tahara, A1    Kurosaki, E2    Yokono, M3
  • 54
    • 84911942671 scopus 로고    scopus 로고
    • The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity
    • Oelze M, Kröller-Schön S, Welschof P, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One. 2014;9:e112394.
    • (2014) PLoS One , vol.9 , pp. e112394
    • Oelze, M1    Kröller-Schön, S2    Welschof, P3
  • 55
    • 85021409196 scopus 로고    scopus 로고
    • The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
    • Steven S, Oelze M, Hanf A, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 2017;13:370–385.
    • (2017) Redox Biol , vol.13 , pp. 370-385
    • Steven, S1    Oelze, M2    Hanf, A3
  • 56
    • 85020437160 scopus 로고    scopus 로고
    • Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors
    • Wysham CH, Lefebvre P, Pilon D, et al. Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors. BMC Endocr Disord. 2017;17:32.
    • (2017) BMC Endocr Disord , vol.17 , pp. 32
    • Wysham, CH1    Lefebvre, P2    Pilon, D3
  • 57
    • 85027194727 scopus 로고    scopus 로고
    • Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus
    • Molugulu N, Yee LS, Ye YT, et al. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus. Diabetes Res Clin Pract. 2017;132:157–168.
    • (2017) Diabetes Res Clin Pract , vol.132 , pp. 157-168
    • Molugulu, N1    Yee, LS2    Ye, YT3
  • 58
    • 84969784577 scopus 로고    scopus 로고
    • Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease
    • Leiter LA, Cefalu WT, de Bruin TW, et al. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes Obes Metab. 2016;18:766–774.
    • (2016) Diabetes Obes Metab , vol.18 , pp. 766-774
    • Leiter, LA1    Cefalu, WT2    de Bruin, TW3
  • 59
    • 85015840398 scopus 로고    scopus 로고
    • Sodium-glucose co-transporter 2 inhibitors reduce the abdominal visceral fat area and may influence the renal function in patients with type 2 diabetes
    • Tosaki T, Kamiya H, Himeno T, et al. Sodium-glucose co-transporter 2 inhibitors reduce the abdominal visceral fat area and may influence the renal function in patients with type 2 diabetes. Intern Med. 2017;56:597–604.
    • (2017) Intern Med , vol.56 , pp. 597-604
    • Tosaki, T1    Kamiya, H2    Himeno, T3
  • 60
    • 84864371186 scopus 로고    scopus 로고
    • Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats
    • Devenny JJ, Godonis HE, Harvey SJ, et al. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring). 2012;20:1645–1652.
    • (2012) Obesity (Silver Spring) , vol.20 , pp. 1645-1652
    • Devenny, JJ1    Godonis, HE2    Harvey, SJ3
  • 61
    • 84858020943 scopus 로고    scopus 로고
    • Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin
    • Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–1031.
    • (2012) J Clin Endocrinol Metab , vol.97 , pp. 1020-1031
    • Bolinder, J1    Ljunggren, Ö2    Kullberg, J3
  • 62
    • 84884167643 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
    • Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941–950.
    • (2013) Lancet , vol.382 , pp. 941-950
    • Cefalu, WT1    Leiter, LA2    Yoon, KH3
  • 63
    • 85021690949 scopus 로고    scopus 로고
    • Effects of canagliflozin on weight loss in high-fat diet-induced obese mice
    • Ji W, Zhao M, Wang M, et al. Effects of canagliflozin on weight loss in high-fat diet-induced obese mice. PLoS One. 2017;12:e0179960.
    • (2017) PLoS One , vol.12 , pp. e0179960
    • Ji, W1    Zhao, M2    Wang, M3
  • 64
    • 85020077721 scopus 로고    scopus 로고
    • SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice
    • Xu L, Nagata N, Nagashimada M, et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. 2017;20:137–149.
    • (2017) EBioMedicine , vol.20 , pp. 137-149
    • Xu, L1    Nagata, N2    Nagashimada, M3
  • 65
    • 85027691344 scopus 로고    scopus 로고
    • Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet
    • Hira T, Koga T, Sasaki K, et al. Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet. Biochem Biophys Res Commun. 2017;492:161–165.
    • (2017) Biochem Biophys Res Commun , vol.492 , pp. 161-165
    • Hira, T1    Koga, T2    Sasaki, K3
  • 66
    • 84880323061 scopus 로고    scopus 로고
    • Look AHEAD research group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
    • Wing RR, Bolin P, Brancati FL, et al; Look AHEAD research group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–154.
    • (2013) N Engl J Med , vol.369 , pp. 145-154
    • Wing, RR1    Bolin, P2    Brancati, FL3
  • 67
    • 84975789692 scopus 로고    scopus 로고
    • Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism
    • Briand F, Mayoux E, Brousseau E, et al. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes. 2016;65:2032–2038.
    • (2016) Diabetes , vol.65 , pp. 2032-2038
    • Briand, F1    Mayoux, E2    Brousseau, E3
  • 68
    • 85010202013 scopus 로고    scopus 로고
    • Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
    • Hayashi T, Fukui T, Nakanishi N, et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017;16:8.
    • (2017) Cardiovasc Diabetol , vol.16 , pp. 8
    • Hayashi, T1    Fukui, T2    Nakanishi, N3
  • 69
    • 85016992878 scopus 로고    scopus 로고
    • Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
    • Fadini GP, Bonora BM, Zatti G, et al. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol. 2017;16:42.
    • (2017) Cardiovasc Diabetol , vol.16 , pp. 42
    • Fadini, GP1    Bonora, BM2    Zatti, G3
  • 70
    • 84975853831 scopus 로고    scopus 로고
    • CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
    • Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care. 2016;39:1108–1114.
    • (2016) Diabetes Care , vol.39 , pp. 1108-1114
    • Ferrannini, E1    Mark, M2    Mayoux, E.3
  • 71
    • 84975840750 scopus 로고    scopus 로고
    • Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis
    • Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39:1115–1122.
    • (2016) Diabetes Care , vol.39 , pp. 1115-1122
    • Mudaliar, S1    Alloju, S2    Henry, RR.3
  • 72
    • 84964608804 scopus 로고    scopus 로고
    • Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes
    • Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65:1190–1195.
    • (2016) Diabetes , vol.65 , pp. 1190-1195
    • Ferrannini, E1    Baldi, S2    Frascerra, S3
  • 73
    • 84955176428 scopus 로고    scopus 로고
    • Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative
    • von Lueder TG, Girerd N, Atar D, et al.; High-Risk Myocardial Infarction Database Initiative Investigators. Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative. Eur J Heart Fail. 2015;17:1144–1151.
    • (2015) Eur J Heart Fail , vol.17 , pp. 1144-1151
    • von Lueder, TG1    Girerd, N2    Atar, D3
  • 74
    • 84958043610 scopus 로고    scopus 로고
    • Effect of allopurinol on cardiovascular outcomes in hyperuricemic patients: a cohort study
    • e2
    • Larsen KS, Pottegård A, Lindegaard HM, et al. Effect of allopurinol on cardiovascular outcomes in hyperuricemic patients: a cohort study. Am J Med. 2016;129:299–306.e2.
    • (2016) Am J Med , vol.129 , pp. 299-306
    • Larsen, KS1    Pottegård, A2    Lindegaard, HM3
  • 75
    • 84857408980 scopus 로고    scopus 로고
    • Minireview: glucagon in stress and energy homeostasis
    • Jones BJ, Tan T, Bloom SR. Minireview: glucagon in stress and energy homeostasis. Endocrinology. 2012;153:1049–1054.
    • (2012) Endocrinology , vol.153 , pp. 1049-1054
    • Jones, BJ1    Tan, T2    Bloom, SR.3
  • 76
    • 84983591995 scopus 로고    scopus 로고
    • Glucagon and heart in type 2 diabetes: new perspectives
    • Ceriello A, Genovese S, Mannucci E, et al. Glucagon and heart in type 2 diabetes: new perspectives. Cardiovasc Diabetol. 2016;15:123.
    • (2016) Cardiovasc Diabetol , vol.15 , pp. 123
    • Ceriello, A1    Genovese, S2    Mannucci, E3
  • 77
    • 84893872877 scopus 로고    scopus 로고
    • Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
    • Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499–508.
    • (2014) J Clin Invest , vol.124 , pp. 499-508
    • Ferrannini, E1    Muscelli, E2    Frascerra, S3
  • 78
    • 85021849793 scopus 로고    scopus 로고
    • Canagliflozin slows progression of renal function decline independently of glycemic effects
    • Heerspink HJ, Desai M, Jardine M, et al. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017;28:368–375.
    • (2017) J Am Soc Nephrol , vol.28 , pp. 368-375
    • Heerspink, HJ1    Desai, M2    Jardine, M3
  • 79
    • 85020459778 scopus 로고    scopus 로고
    • EMPA-REG OUTCOME: the nephrologist’s point of view
    • Wanner C. EMPA-REG OUTCOME: the nephrologist’s point of view. Am J Cardiol. 2017;120(1S):S59–S67.
    • (2017) Am J Cardiol , vol.120 , Issue.1S , pp. S59-S67
    • Wanner, C.1
  • 80
    • 85106925065 scopus 로고    scopus 로고
    • Is an increase in serum magnesium one of the causes of cardiovascular events reduction in the EMPA-REG OUTCOME Study?
    • Yanagawa T. Is an increase in serum magnesium one of the causes of cardiovascular events reduction in the EMPA-REG OUTCOME Study? J Clin Med Res. 2017;9:449–450.
    • (2017) J Clin Med Res , vol.9 , pp. 449-450
    • Yanagawa, T.1
  • 81
    • 84902164918 scopus 로고    scopus 로고
    • Role of magnesium in cardiovascular diseases
    • Kolte D, Vijayaraghavan K, Khera S, et al. Role of magnesium in cardiovascular diseases. Cardiol Rev. 2014;22:182–192.
    • (2014) Cardiol Rev , vol.22 , pp. 182-192
    • Kolte, D1    Vijayaraghavan, K2    Khera, S3
  • 82
    • 85006172812 scopus 로고    scopus 로고
    • Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME Trial?
    • Verma S, Garg A, Yan AT, et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME Trial? Diabetes Care. 2016;39:e212–e213.
    • (2016) Diabetes Care , vol.39 , pp. e212-e213
    • Verma, S1    Garg, A2    Yan, AT3
  • 83
    • 85017099681 scopus 로고    scopus 로고
    • Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?
    • Shi X, Verma S, Yun J, et al. Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial? Mol Cell Biochem. 2017;433:97–102.
    • (2017) Mol Cell Biochem , vol.433 , pp. 97-102
    • Shi, X1    Verma, S2    Yun, J3
  • 84
    • 85032620814 scopus 로고    scopus 로고
    • Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action
    • Packer M, Anker SD, Butler J, et al. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017;2:1025–1029.
    • (2017) JAMA Cardiol , vol.2 , pp. 1025-1029
    • Packer, M1    Anker, SD2    Butler, J3
  • 85
    • 84898434447 scopus 로고    scopus 로고
    • Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations
    • Scheen AJ. Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug MetabToxicol. 2014;10:647–663.
    • (2014) Expert Opin Drug MetabToxicol , vol.10 , pp. 647-663
    • Scheen, AJ.1
  • 86
    • 85021120165 scopus 로고    scopus 로고
    • A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus
    • Avogaro A, Giaccari A, Fioretto P, et al. A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. Expert Rev Clin Pharmacol. 2017;10:763–772.
    • (2017) Expert Rev Clin Pharmacol , vol.10 , pp. 763-772
    • Avogaro, A1    Giaccari, A2    Fioretto, P3
  • 87
    • 84987668892 scopus 로고    scopus 로고
    • Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study
    • Tanaka A, Murohara T, Taguchi I, et al.; PROTECT Study Investigators. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study. Cardiovasc Diabetol. 2016;15:133.
    • (2016) Cardiovasc Diabetol , vol.15 , pp. 133
    • Tanaka, A1    Murohara, T2    Taguchi, I3
  • 88
    • 85018499284 scopus 로고    scopus 로고
    • Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial
    • Tanaka A, Shimabukuro M, Okada Y, et al.; EMBLEM Trial Investigators. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. Cardiovasc Diabetol. 2017;16:48.
    • (2017) Cardiovasc Diabetol , vol.16 , pp. 48
    • Tanaka, A1    Shimabukuro, M2    Okada, Y3
  • 89
    • 84978252552 scopus 로고    scopus 로고
    • Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design
    • Singh JS, Fathi A, Vickneson K, et al. Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovasc Diabetol. 2016;15:97.
    • (2016) Cardiovasc Diabetol , vol.15 , pp. 97
    • Singh, JS1    Fathi, A2    Vickneson, K3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.